NEW YORK (GenomeWeb) – Novigenix has signed a commercialization agreement with Dr Risch Medical Laboratory to distribute its PCR-based Colox blood test for early detection of colorectal cancer, giving the firm access to the Swiss German market and Lichtenstein.
The agreement comes after a similar one with Unilabs to target the French Swiss market and is part of the firm's overall European expansion plans.
Dr Risch will also soon launch a full range of diagnostic colorectal cancer services, including gold-standard fecal immunochemical tests to detect blood in stool.
"We are delighted to have found in Dr Risch a solid and science-driven partner that is dedicated to help reduce cancer mortality through early detection of colorectal cancer and advanced polyps," said Nicolas Demierre, COO of Novigenix. "Together with data from our ongoing, prospective 1,000-patient study PROSPEROS, we expect that our collaboration with Dr Risch will significantly contribute to our growing body of clinical evidence of Colox in routine medical practice."